Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study

• Published in: Lancet neurology 2023-09, Vol.22 (9), p.826-833
• Main Authors: Abdelhak, Ahmed, Petermeier, Franziska, Benkert, Pascal, Schädelin, Sabine, Oechtering, Johanna, Maleska Maceski, Aleksandra, Kabesch, Michael, Geis, Tobias, Laub, Otto, Leipold, Georg, Gobbi, Claudio, Zecca, Chiara, Green, Ari, Tumani, Hayrettin, Willemse, Eline, Wiendl, Heinz, Granziera, Cristina, Kappos, Ludwig, Leppert, David, Waubant, Emmanuelle, Wellmann, Sven, Kuhle, Jens
• Format: Article
• Language: English
• Subjects: Adolescents; Age; Antibodies; Biomarkers; Children; Coronaviruses; COVID-19; Datasets; Dependent variables; Disease; Epilepsy; Glycoproteins; Health care; Multiple sclerosis; Myelin; Neonates; Neuroimmunology; Neurological diseases; Oligodendrocyte-myelin glycoprotein; Patients; Pediatrics; Population; Severe acute respiratory syndrome coronavirus 2; Teenagers; Traumatic brain injury
• ISSN: 1474-4422; 1474-4465
• DOI: 10.1016/S1474-4422(23)00210-7

Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability. To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0–22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1–19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany). Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0–12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0–20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93–0·94], p